OnCore Login

Return to Trial Database

GI03-53

A Phase II Trial of Preoperative Capecitabine Plus Irinotecan Followed by Combined Modality Capecitabine and Radiation for Locally Advanced Rectal Cancer – GI03-53

Status

Study Completed

Cancer Type(s)

Rectal

Study Contact

Publications

A Phase II trial of Neoadjuvant Capecitabine plus Irinotecan Followed by Combined Modality Capecitabine and Radiation Therapy for Patients with Locally Advanced Rectal Cancer
  • EG Chiorean, M Schiel, S Sanghani, M Yu, J Shen, H Cardenes, J LeBlanc, B Robb, PJ Loehrer, J Harvey
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer
  • EG Chiorean, S Sanghani, MA Schiel, M Yu, M Burns, Y Tong, DT Hinkle, N Coleman, B Robb, J LeBlanc, R Clark, J Bufill, C Curie, PJ Loehrer, H Cardenes
Phase II Trial of Neoadjuvant Capecitabine (Cp) with Irinotecan (Ir) followed by Capecitabine-based Chemoradiotherapy (CRT) for Patients (pts) with Locally Advanced Rectal Cancer (LARC)
  • H Cardenes, S Sanghani, M Burns, B Robb, D Hinkle, C Johnson, M Yu, C Currie, P Loehrer, E Chiorean

Trial Locations

All sites in which the trial GI03-53 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278